Holen Sie sich die Stockscreener-App
4.65
9.93%
0.42
Handel nachbörslich:
4.61
-0.04
-0.86%
Schlusskurs vom Vortag:
$4.23
Offen:
$4.19
24-Stunden-Volumen:
51,425
Relative Volume:
0.80
Marktkapitalisierung:
$3.15M
Einnahmen:
$5.49M
Nettoeinkommen (Verlust:
$-6.35M
KGV:
-0.879
EPS:
-5.29
Netto-Cashflow:
$-6.51M
1W Leistung:
-8.46%
1M Leistung:
-19.83%
6M Leistung:
-29.37%
1J Leistung:
-38.83%
1-Tages-Spanne:
$4.09
$4.99
1-Wochen-Bereich:
$3.65
$5.1341
52-Wochen-Spanne:
$2.414
$15.70
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Firmenname
Inmed Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 669-7207
Adresse
1445-885 WEST GEORGIA ST., VANCOUVER
Vergleichen Sie INM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| INM | 4.65 | 3.15M | 5.49M | -6.35M | -6.51M | -5.29 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Inmed Pharmaceuticals Inc Aktie (INM) Neueste Nachrichten
InMed Pharmaceuticals (FRA:MWG) EBITDA : €-6.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Earnings per Share (Diluted) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Asset Turnover : 0.11 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Intrinsic Value: DCF (Earni - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Free Cash Flow : €-6.08 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) COGS-to-Revenue : 0.61 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Earnings Yield (Joel Greenb - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Price-to-Owner-Earnings : (As of Nov. 21, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash-to-Debt : 5.28 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted PB Rati - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted FCF per Share : €-485.97 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted Book pe - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Forward Dividend Yield % : 0.00% (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted PS Rati - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Inventories, Finished Goods : €0.84 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year Book Growth Rate : -64.40% (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Current Liabilities : €0.21 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EPS (Basic) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Long-Term Liabilities : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash From Discontinued Inve - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Long Term Assets : €0.09 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Ratio : 3.89 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash Flow from Investing : €-0.01 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EBIT : €-6.66 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Peter Lynch Fair Value : €-1,493.15 (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cash From Other Investing A - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Long-Term Capital Lease Obl - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Total Stockholders Equity : €7.56 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EV-to-EBITDA : 0.22 (As of Nov. 20, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cyclically Adjusted Revenue per Share : €68.91 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Purchase Of Investment : €-0.04 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Change In Receivables : €-0.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year EPS without NRI Grow - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EPS without NRI : €-59.73 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Other Stockholders Equity : €-0.00 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Change In Inventory : €-0.28 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Net Issuance of Preferred S - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) EPS (Diluted) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Short-Term Capital Lease Ob - GuruFocus.com
InMed’s Study Highlights Cannabinol’s Potential in Skincare - TipRanks
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System - Newsfile
InMed Pharmaceuticals Reports Improved Quarterly Earnings - TipRanks
InMed Pharmaceuticals (STU:MWG) Debt-to-EBITDA : -0.13 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) 3-Year Revenue Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Growth Rank : 0 (As of Nov. 17, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Issuance of Stock : €4.27 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Change In Working Capital : €-0.33 Mil (TTM As of Jun. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Net Issuance of Debt : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Finanzdaten der Inmed Pharmaceuticals Inc-Aktie (INM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Inmed Pharmaceuticals Inc-Aktie (INM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HULL ANDREW | Director |
Feb 21 '24 |
Buy |
0.39 |
37,500 |
14,625 |
38,258 |
| ADAMS ERIC A | President & CEO |
Feb 20 '24 |
Buy |
0.36 |
41,600 |
14,922 |
43,959 |
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):